Arbutus to Receive $950M Upfront, Up to $2.25B From Moderna Settlement
Arbutus Biopharma will receive $950 million upfront in July 2026 and up to an additional $1.3 billion from Moderna to resolve global patent claims over lipid nanoparticle vaccine technology. The deal grants Moderna a global non-exclusive license to Arbutus’s LNP delivery patents and removes all pending infringement suits.
1. Settlement Terms
Under the agreement, Moderna will pay Arbutus $950 million in July 2026 and may pay up to an additional $1.3 billion depending on the outcome of its appeal on government contractor immunity under Section 1498.
2. Financial Impact
The upfront payment provides a significant cash infusion that will bolster Arbutus’s balance sheet and support ongoing R&D, while the contingent payment could more than double the total proceeds if Moderna’s appeal fails.
3. Patent License Agreement
Arbutus will grant Moderna a global non-exclusive license to its LNP delivery technology for SM-102 mRNA vaccines and provide a covenant not to sue, with no future royalties owed on covered products.
4. Company Outlook
Management describes the settlement as a transformative outcome that recognizes Arbutus’s pivotal role in LNP development and removes a major legal overhang, allowing focus on advancing its nucleic acid delivery platform.